The neurobiology of psychedelic drugs: implications for the treatment of mood disorders
The DOI matches its Crossref record; 149 of the 149 references it cites were found in a registry or an index.
Abstract
After a pause of nearly 40 years in research into the effects of psychedelic drugs, recent advances in our understanding of the neurobiology of psychedelics, such as lysergic acid diethylamide (LSD), psilocybin and ketamine have led to renewed interest in the clinical potential of psychedelics in the treatment of various psychiatric disorders. Recent behavioural and neuroimaging data show that psychedelics modulate neural circuits that have been implicated in mood and affective disorders, and can reduce the clinical symptoms of these disorders. These findings raise the possibility that research into psychedelics might identify novel therapeutic mechanisms and approaches that are based on glutamate-driven neuroplasticity.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It has been suggested that the persisting therapeutic effects of psychedelics are attributable to a similar biological mechanism (39, 40).”
From Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics. (2021) · cites this paper as [39]
Citations
Cites
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856 · cited 1×
“5 mg per kg), and this effect was sustained for at least 72 hour”
BackgroundA randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330 · cited 1×
“Dissociative anaesthetics mimic the positive and the negative symptoms (social withdrawal and apathy) of schizophrenia through antagonism at NMDA ( N -methyl- D -aspartate) glutamate receptor”
BackgroundMoghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793 · cited 1×
“Systemic administration of non-competitive NMDA antagonists, such as ketamine, PCP and MK-801 (also known as dizocilpine), in rats markedly increases glutamate release in the mPF”
BackgroundDavis, H. S. (1966) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1966.03100200106038 · Cited by 1,719
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684 · cited 1×
“and was rated as among the most personally meaningful experience”
Background(1990) · Springer eBooks · doi:10.1007/978-3-642-74034-3 · Cited by 1,523
Anis, N. A., Berry, S. C., Burton, N. R., & Lodge, D. (1983) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1983.tb11031.x · Cited by 1,399
(2009) · Elsevier eBooks · doi:10.1016/c2009-1-03742-3 · Cited by 1,308
Homayoun, H., & Moghaddam, B. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.2213-07.2007 · Cited by 1,231 · cited 1×
“These effects are probably due to a blockade of NMDA receptors on GABA (γ-aminobutyric acid)-ergic interneuron”
Background
Research works printed but not linked: 6
- Hofmann, A. in Chemical Constitution and Pharmacodynamic Actions (ed. Burger, A.) 169–235 (M.Dekker, New York, 1968).
- Dittrich, A. in 50 Years of LSD. Current Status and Perspectives of Hallucinogens (eds Pletscher, A. & Ladewig, D.) 101–118 (Parthenon, New York, 1994).
- Hoffer, A. in The Uses and Implications of Hallucinogenic Drugs (eds Aaronson, B. & Osmond, H.) 357–366 (Hogarth Press, London, 1970).
- Leuner, H. in 50 Years of LSD: Current Status and Perspectives of Hallucinogen Research (eds Pletscher, A. & Ladewig, D.) 175–189 (Parthenon, New York, 1994).
- Crocket, R., Sandison, R. A. & Walk, A. in Proc. R. Med–Psychol. Assoc. (Lewis & Co., London, 1963).
- Leuner H. in Ethnopsychotherapie (eds Dittrich, A. & Scharfetter, C.) 151–161 (Enke, Stuttgard, 1987)
Cited by
Items 601–700 of 721
The Relationship between Anxiety Vulnerability Factors, Psychedelic Drug Use and Trait Anxiety
Ursa, F. (2016) · Lund University Publications Student Papers (Lund University)
Peng, L. (2014) · Journal of International Crisis and Risk Communication Research
Von einem alten Anästhetikum zu neuen Therapiestrategien
Sartorius, A. (2016) · NeuroTransmitter · doi:10.1007/s15016-016-5447-1
LAS PROPIEDADES FARMACOCINÉTICAS DEL AYAHUASCA THE PHARMACOLOGICAL PROPERTIES OF AYAHUASCA
Cornejo, G. S. E., & Cornejo, E. (2015) · Liberabit Revista Peruana de Psicología
Photophysics of N,N-dimethyl-3-(1-indolyl)propan-1-ammonium chloride and related derivatives
Safko, T. M., Kertész, M., & Weiss, R. G. (2017) · Photochemical & Photobiological Sciences · doi:10.1039/c7pp00199a
Literature review: Considerations for Psychedelic Research
Hawkins, C. (2013) · UC Merced Undergraduate Research Journal · doi:10.5070/m451020759
Psychische Störungen infolge anderer psychotroper Substanzen
Soyka, M. (2017) · Elsevier eBooks · doi:10.1016/b978-3-437-22881-0.00017-4
Sahai‐Srivastava, S. (2018) · Springer eBooks · doi:10.1007/978-3-319-91491-6_6
Everything old is new again: are psychedelic medicines poised to take mental health by storm?
Raison, C. L. (2018) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12975
“Psychedelics snuck into modern medicine in the mid-1990s with the pioneering work of Rick Strassman and colleagues, who reported on the biological and behavioural effects of the rapidly acting agent N,N-dimethyltryptamine (DMT) (2, 3) and with the multiple basic science studies conducted by Franz Vollenweider and coll…”
Jeannin, J.-M. (2013) · Schweizerische Zeitschrift für Ganzheitsmedizin / Swiss Journal of Integrative Medicine · doi:10.1159/000353751
Camacho, M. B. (2018) · Illinois Digital Environment for Access to Learning and Scholarship (University of Illinois at Urbana-Champaign)
P.210 A single dose of LSD facilitates long-lasting fear erasure in mice
Moliner, R., Elsilä, L. V., Casarotto, P. C., Korpi, E. R., & Ċastrén, E. (2020) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2019.12.036
Trip: Psychedelics, Alienation, and Change
Schnipke, B. D. (2020) · American Journal of Psychiatry Residents Journal · doi:10.1176/appi.ajp-rj.2020.150310
Bahi, C. (2020) · arXiv (Cornell University) · doi:10.48550/arxiv.2007.08429 · Cited by 2
“Activation of the prefrontal network and glutamate release by psychedelics (Vollenweider and Kometer, 2010)”
InfluentialConclusion: What Is To Be Done?
R.Kleiman, M. A., Caulkins, J. P., & Hawken, A. (2011) · Oxford University Press eBooks · doi:10.1093/wentk/9780199764518.003.0012
R.Kleiman, M. A., Caulkins, J. P., & Hawken, A. (2011) · Oxford University Press eBooks · doi:10.1093/wentk/9780199764518.003.0003
What Are the Benefits of Drug Use?
R.Kleiman, M. A., Caulkins, J. P., & Hawken, A. (2011) · Oxford University Press eBooks · doi:10.1093/wentk/9780199764518.003.0008
Does International Drug Dealing Support Terrorism?
R.Kleiman, M. A., Caulkins, J. P., & Hawken, A. (2011) · Oxford University Press eBooks · doi:10.1093/wentk/9780199764518.003.0010
When It Comes To Drugs, Why Can’t We Think Calmly and Play Nice?
R.Kleiman, M. A., Caulkins, J. P., & Hawken, A. (2011) · Oxford University Press eBooks · doi:10.1093/wentk/9780199764518.003.0011
R.Kleiman, M. A., Caulkins, J. P., & Hawken, A. (2011) · Oxford University Press eBooks · doi:10.1093/wentk/9780199764518.003.0005
R.Kleiman, M. A., Caulkins, J. P., & Hawken, A. (2011) · Oxford University Press eBooks · doi:10.1093/wentk/9780199764518.003.0006
How Does Drug-Law Enforcement Work?
R.Kleiman, M. A., Caulkins, J. P., & Hawken, A. (2011) · Oxford University Press eBooks · doi:10.1093/wentk/9780199764518.003.0004
Can Drug Problems Be Dealt With at the Source?
R.Kleiman, M. A., Caulkins, J. P., & Hawken, A. (2011) · Oxford University Press eBooks · doi:10.1093/wentk/9780199764518.003.0009
Why Is “Drug” the Name of a Problem?
R.Kleiman, M. A., Caulkins, J. P., & Hawken, A. (2011) · Oxford University Press eBooks · doi:10.1093/wentk/9780199764518.003.0002
Jalal, B. (2021) · Medical Hypotheses · doi:10.1016/j.mehy.2021.110521 · Cited by 3
Chapter 15. Neurobiology and Treatment of Hallucinogen Use Disorder
Dakwar, E. (2021) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615373970.kb15 · Cited by 1
Johansen, L., Liknaitzky, P., Nedeljkovic, M., Mastin‐Purcell, L., & Murray, G. (2020) · Research Square · doi:10.21203/rs.3.rs-121894/v1
Ayahuasca as a Versatile Therapeutic Agent: From Molecules to Metacognition and Back
Valle, M., Domínguez‐Clavé, E., Elices, M., Pascual, J. C., Soler, J., Morales-Garcia, J. A., Pérez‐Castillo, A., & Riba, J. (2021) · Springer eBooks · doi:10.1007/978-3-030-55688-4_1 · Cited by 1
Betzler, F., & Majić, T. (2016) · Springer eBooks · doi:10.1007/978-3-642-55214-4_48-1
Fulton, B. S. (2014) · Wiley eBooks · doi:10.1002/9781118943670.refs
Drogen- und Medikamentenabhängigkeit
Majić, T., Kienast, T., Heinz, A., & Soyka, M. (2017) · Springer eBooks · doi:10.1007/978-3-662-49295-6_62 · Cited by 1
Lysergic Acid Diethylamide and Mescaline
(2014) · John Wiley & Sons, Inc. eBooks · doi:10.1002/9781118850046.ch9
R.Kleiman, M. A., Caulkins, J. P., & Hawken, A. (2011) · Oxford University Press eBooks · doi:10.1093/wentk/9780199764518.003.0001
A KETAMIN HATÁSA A TERÁPIAREZISZTENS MAJOR DEPRESSZIÓRA
SZTE BTK, P. I., & Peszeki, N. (2017) · Psychologia Hungarica Caroliensis · doi:10.12663/psyhung.5.2017.1.3
Mason, N. L. (2021) · Research Publications (Maastricht University) · doi:10.26481/dis.20210608nm · Cited by 1
Faculty Opinions recommendation of Psychedelics promote structural and functional neural plasticity.
Chapman, E. R., & Vevea, J. (2018) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.733441066.793547403
D’Aprile, I. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819641-0.00125-0
Sontheimer, H. W. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821228-8.00015-9
Forstmann, M., & Sagioglou, C. (2021) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/2489x
Cardeña, E. (2017) · Wiley eBooks · doi:10.1002/9781119132363.ch13
Uso da psilocibina como ferramenta psicoterapêutica no tratamento da depressão: uma revisão
da Silva, J. R., da Costa, S. M., & da Silva, D. P. (2021) · Scire Salutis · doi:10.6008/cbpc2236-9600.2022.001.0035 · Cited by 2
Pharmacology of Hallucinations in Several Mechanism of Action in Single Symptom
{"name":"Sreenivasulu M", ". C., {"name":"Puttam Prameela", ". C., & {"name":"Penabaka Venugopalaiah", ". C. (2022) · Future Journal of Pharmaceuticals and Health Sciences · doi:10.26452/fjphs.v2i4.310
Manuel de Yale pour la Thérapie de la Dépression Assistée par la PsilocybinePreprint
Guss, J. R., Krause, R., & Sloshower, J. (2022) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/r96tc
IsHak, W. W., Magakian, N., Ishak, W. W., Mikhail, A. A., & Lim, R. F. (2023) · Springer eBooks · doi:10.1007/978-3-031-15401-0_25
Tetem, J., Fischmann, T., & Möller, T. J. (2023) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/ztyxh
Effects of psychedelics on neurogenesis and brain plasticity: A systematic reviewPreprint
da Cruz, R. V. L., Leão, R. N., & Moulin, T. C. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.07.19.549676
Psilocybin's Emerging Role in Combating Depressive Disorder
Jaremek, A., Kępa, J., Kandefer, N., Wyszkowski, M., Grabarczyk, A., Pawlak, A., Grad, S., Gregorek, M., & Gregorek, P. (2023) · Journal of Education Health and Sport · doi:10.12775/jehs.2023.40.01.011 · Cited by 1
“131 the 5-HT2A receptor being the primary one (6).”
Orlowski, P., Hobot, J., Ruban, A., Szczypiński, J., & Bola, M. (2023) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/uzwa3
Elder, H. J., Walentiny, D. M., & Beardsley, P. M. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4658637
Toledo, M. M. V. (2023) · Cultura y Droga · doi:10.17151/culdr.2023.28.35.5
“En este escenario se ha sugerido que el efecto antidepresivo de la psilocibina subyacería en su capacidad de promover la plasticidad estructural y funcional en regiones como la corteza prefrontal y el hipocampo (Ly et al. , 2018; Vollenweider & Kometer, 2010).”
BackgroundBostancıklıoğlu, M. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15411
“6 These systems could potentially impact the pancreas through their effects on the autonomic nervous system.”
BackgroundMuñoz, E. G. (2018) · Global Journal of Addiction & Rehabilitation Medicine · doi:10.19080/gjarm.2018.05.555671
Breeksema, J. J. (2024) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.912040905 · Cited by 1
POTENCIAL TERAPÊUTICO DA PSILOCIBINA NO TRATAMENTO DA DEPRESSÃO: UMA REVISÃO NARRATIVA
Coelho, B. B., Astrath, I. F., & Vismari, L. (2024) · Congresso Nacional de Neurologia Multidisciplinar · doi:10.29327/1399766.1-5
Schaller, A., Bourquin, G., Araujo, I. A., & Ljuslin, M. (2023) · Revue internationale de soins palliatifs · doi:10.3917/inka.242.0098
Afrooghe, A., Ahmadi, E., Lesani, A., Mehranjani, M. S., Elahi, M. M., Babaei, M., Shayan, M., Shafaroodi, H., Jafari, R. M., Foroumadi, A., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4891179
Mattu, J., & Sullivan, J. A. (2024) · Oxford University Press eBooks · doi:10.1093/oso/9780192898371.003.0007
Ketamine and Psilocybin Differentially Impact Sensory Learning During the Mismatch NegativityPreprint
Allohverdi, S. G., Soltanzadeh, M., Schmidt, A., Charlton, C. E., Hauke, D. J., Karvelis, P., Vollenweider, F. X., & Diaconescu, A. O. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.21203/rs.3.rs-4492873/v1 · Cited by 1
Self-citationMajić, T., Gouzoulis‐Mayfrank, E., & Schaub, M. (2024) · Elsevier eBooks · doi:10.1016/b978-3-437-21074-7.00015-0 · Cited by 3
Advancements in drug intervention research for stress-related psychiatric disorders
Yan, G. A. O., Xu, N.-L., Chen, Z., Han, M., Zhu, Y., Wu, W., Zhao, M., Yang, W., Wang, Z., Duan, S., et al. (2025) · Scientia Sinica Vitae · doi:10.1360/ssv-2024-0359
Elder, H., Walentiny, D. M., & Beardsley, P. M. (2024) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2025.174004
Effects of a single dose of psilocybin on diet-induced weight loss in obese mice
Keenan, R. J., Haque, R. T., Jin, X., Mustafa, T., Homman‐Ludiye, J., Elysee, K., Wee, Z. S., Simonds, S. E., Foldi, C. J., & Cowley, M. A. (2026) · Translational Psychiatry · doi:10.1038/s41398-026-03995-7
Repurposed Drugs of Abuse (Stimulants, Ketamine, and Psychedelics): Focus on Risks
Souza‐Marques, B., Caliman‐Fontes, A. T., Leal, G. C.-G., Bandeira, I. D., Mello, R. P., Alves-Pereira, R., & Quarantini, L. C. (2025) · Springer eBooks · doi:10.1007/978-3-031-85519-1_28
Neurocognitive Factors in Spiritual Experiences and Practices
Kohls, N. B., & Giordano, J. (2025) · Springer eBooks · doi:10.1007/978-3-031-38971-9_1976-1 · Cited by 1
Psychedelic agents for treatment-resistant depression
Gukasyan, N., & Griffiths, R. R. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824067-0.00014-1
Context-dependent structurally informed effective connectivity under psilocybinPreprint
Greaves, M. D., Barta, T., Novelli, L., Stoliker, D., & Razi, A. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.08.18.671000
“In our analysis, we considered a single brain network comprising regions previously implicated in psychedelic action: the medial prefrontal cortex (MPFC), posterior cingulate cortex (PCC), bilateral anterior insular (AI), bilateral hippocampus, and thalamus 3,10,20,21 .”
White, A. M., Bauer, A. D., Faumont, S., & Lockery, S. R. (2025) · PLoS ONE · doi:10.1371/journal.pone.0329538 · Cited by 2
“Growing preclinical [1–4] and clinical evidence [5–7] suggest that psychedelics are effective in treating conditions such as depression, post-traumatic stress disorder, and substance use disorder [8–10].”
Spitz, N. A. (2025) · Springer eBooks · doi:10.1007/978-3-031-57159-6_5-1
Pharmacotherapies for Hallucinogen Use Disorder
Spitz, N. A. (2025) · Springer eBooks · doi:10.1007/978-3-031-57159-6_75-1
Calin, A., Burlec, A. F., Mircea, C., Macovei, I., Hăncianu, M., & Corciovă, A. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14186613 · Cited by 3
“…point of view, psilocybin acts predominantly through its active metabolite, psilocin, which crosses the blood–brain barrier (BBB) and binds with increased affinity to serotonin-specific 5-HT2A receptors, located mainly in the prefrontal cortex, anterior cingulate, and parietal cortex [35,36].”
InfluentialPsychedelics: Recent Philosophical Discussions
Letheby, C. (2025) · Springer eBooks · doi:10.1007/978-94-024-2252-8_101
McConnell, P., Raffety, J., Li, A., Steinberg, E., Rahim, S., Valtierra, C., Gazzaley, A. H., Carhart-Harris, R. L., & Pasquini, L. (2025) · Research Square · doi:10.21203/rs.3.rs-7625999/v1
Tsang, V. W. L., Tao, B. K.-L., Olthuis, R., Allard, P., Bhanot, S., Wong, S. L., & Kryskow, P. (2025) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2025.09.032
Rosal, S. P., & Faber, S. C. (2025) · Research Square · doi:10.21203/rs.3.rs-8000629/v1
New treatments for OCD? Evidence for cannabinoids and psychedelics
Ameringen, M. V., Patel, V., Patterson, B. A., Hopkinson, P., & Rahat, M. (2025) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2025.11.021 · Cited by 1
The Potential Therapeutic Effects of MEAI in the Treatment of Alcohol Use Disorder
Ekhlasi, M., Frytz, A., & Nia, A. B. (2025) · Current Addiction Reports · doi:10.1007/s40429-025-00700-4
“Moreover, according to some studies, psychedelic-enhanced neuroplasticity, which may play a role in their therapeutic effects, is also mediated by activation of the 5-HT2A receptors (5-HT2AR) [40, 41], though other studies suggest an independent mechanism [42].”
Chapter 8. Hallucinogens and Phencyclidine
DeVido, J. J., & Epson, M. F. (2025) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9798894550862.lg08
Arias, H., Rudin, D., Ren, X., Liechti, M. E., & Huang, N. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5877054
Greguš, D., Hlinka, J., Tylš, F., Viktorin, V., Viktorinová, M., Bravermanová, A., Androvičová, R., Andrashko, V., Korčák, J., Nikolič, M., et al. (2025) · Psychopharmacology · doi:10.1007/s00213-025-06983-9
Ryan, R. S., Copello, A., & Fox, A. P. (2024) · Figshare · doi:10.6084/m9.figshare.26575175
Medicinal Mushrooms and Mental Disorders: How Mushrooms Affect Anxiety and Depression
Tarki, A., Hajikarim‐Hamedani, A., Rassa, S., & Khosravi, S. (2025) · Nutritional neurosciences · doi:10.1007/978-981-95-2774-8_6
Copeland, J., & Dillon, P. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-398336-7.00074-7
“Tragic Person evolved: Transforming tragedy into hope through new, alternative treatments”
Zimmerman, D. (2025) · Psychoanalysis Self and Context · doi:10.1080/24720038.2025.2604803
“This research suggests that psychedelics increase prefrontal cortex activity and dampen the amygdala’s response to negative stimuli (Vollenweider & Kometer, 2010), potentially fostering deeper therapeutic connections and reducing anxiety.”
Husein, A., Traylor, M., Vest, M. F., Wood, B. J., Brogan, M., Thomas, A., McNeil, S. E., Bhuiyan, M. A. N., Hendricks, P. S., Kelly, J. R., et al. (2025) · Psychedelic Medicine · doi:10.1177/28314425251381806
Mele, M. L., & Rutrecht, H. M. (2026) · Lecture notes in computer science · doi:10.1007/978-3-032-12808-9_8
Psilocin fosters neuroplasticity in iPSC-derived human cortical neuronsPreprint
Schmidt, M., Hoffrichter, A., Davoudi, M., Horschitz, S., Lau, T., Meinhardt, M. W., Spanagel, R., Ladewig, J., Köhr, G., & Koch, P. J. (2026) · eLife · doi:10.7554/elife.104006.2 · Cited by 1
Sympathetic activation but not dissociation linked to ketamine’s sustained antidepressant effect
Andrashko, V., Novak, T., Kopeček, M., Šuláková, A., Knop, V., & Horacek, J. (2026) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253261419636
Sarangal, M. (2026) · American Journal of Psychiatry Residents Journal · doi:10.1176/appi.ajp-rj.2026.210302
Neurotransmitters and Neural Pathways
Schnall, J. S. (2026) · Springer eBooks · doi:10.1007/978-3-031-57159-6_33-1
Psilocybin: Chemical Foundations and Emerging Therapeutic Potential
Patil, S. A., & Hunsberger, H. C. (2026) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/0113895575429775260119043318 · Cited by 1
Leptourgos, P. (2018) · theses.fr (ABES) · doi:10.70675/dafacdb1z9072z4ec2z8cebz0ca09b93b7ce · Cited by 4
Enhanced effect of the hallucinogen DOI in L-DOPA receptor Gpr143-deficient mice
Masukawa, D., Tajika, R., Ichimaru, Y., Kurihara, M., Suzuki, T., & Goshima, Y. (2026) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2026.04.002
Wherefore the Magic? The Evolutionary Role of Psilocybin in Nature
Nicholass, K. J. M., Flis, I., Hanley, M. E., Knight, M. E., Lane, S., Littlejohn, G. R., Thom, M. D. F., Billington, R. A., Boden, R., Cummins, R., et al. (2026) · Ecology and Evolution · doi:10.1002/ece3.73522 · Cited by 4
Sedeek, N., Rivers, C., Williamson, L., Asadi, A., & Grundy, J. G. (2026) · Journal of Affective Disorders · doi:10.1016/j.jad.2026.121891
Cluck, M., Purcell, A. B., Kazan, Z., Robinson, J. O., McGuire, A. L., & Neitzke‐Spruill, L. (2026) · Psychedelics · doi:10.1016/j.psyche.2026.100020
THE PSYCHEDELIC AND KETAMINE RENAISSANCE IN THE FACE OF THE CRISIS IN MODERN PSYCHIATRY
Osipowska, J., Kwolek, M., Judzińska, A., Piech, B., Sobczyńska, K., Ignarska, J., Terbosh, M., `Mzabi, S. K., Trojanowska, E., & Dubaj, M. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.2(50).2026.5605
Basch, R., Cohen, M., & Peled‐Avron, L. (2026) · medRxiv · doi:10.64898/2026.06.18.26355974
dos Santos, J. C. C., Bolan, S. J., da Silva, G. L., Viana, G. L., Rico, E. P., & Gonçalves, C. L. (2026) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2026.06.035
Metadata
- Authors
- Vollenweider, F. X., & Kometer, M.
- Affiliations
- University of Zurich (CH)
- University Hospital Zurich (CH)
- Corresponding author
- Vollenweider, Franz X.
- Venue
- Nature Reviews Neuroscience
- Published
- 2010-08-18
- Volume
- 11
- Issue
- 9
- Pages
- 642-651
- ISSN
- 1471-003X (ISSN-L)
- 1471-0048
- OpenAlex
- W2068751924
- Semantic Scholar
- d95a57f4b1e3288f21a7dab08ebc2fd5ff10a762
- Cited by
- 723
- References
- 149
- Citations by year
- 2026: 55 · 2025: 75 · 2024: 55 · 2023: 64 · 2022: 53 · 2021: 63 · 2020: 50 · 2019: 35 · 2018: 56 · 2017: 37 · 2016: 48 · 2015: 29 · 2014: 24 · 2013: 18 · 2012: 25
- FWCI
- 3.69
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature reviews. Neuroscience (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- psychedelics, mood disorders, serotonergic system, glutamatergic system, dissociative anesthetics, LSD, psilocybin, ketamine, neuroplasticity, neural circuits, psychiatric treatment
- MeSH terms
- Animals, Brain, Hallucinogens, Humans, Models, Neurological, Mood Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.